These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 19074476

  • 1. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
    Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, Wang F, Ackerman A, Karas RH, Molkentin JD, Patten RD.
    Circ Res; 2009 Jan 30; 104(2):265-75, 11p following 275. PubMed ID: 19074476
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W, Dong M, Deng J, Yan D, Liu Y, Xu T, Liu J.
    Am J Physiol Heart Circ Physiol; 2014 Sep 01; 307(5):H792-802. PubMed ID: 25015961
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D, Kim JM, Cha H, Oh JG, Park J, Yun SH, Ju ES, Jeon ES, Hajjar RJ, Park WJ.
    Circ Res; 2008 Mar 28; 102(6):711-9. PubMed ID: 18258855
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Increased cholinergic activity under conditions of low estrogen leads to adverse cardiac remodeling.
    Teixeira VP, Miranda K, Scalzo S, Rocha-Resende C, Silva MM, Tezini GCSV, Melo MB, Souza-Neto FP, Silva KSC, Jesus ICG, Santos AK, de Oliveira M, Szawka RE, Salgado HC, Prado MAM, Poletini MO, Guatimosim S.
    Am J Physiol Cell Physiol; 2021 Apr 01; 320(4):C602-C612. PubMed ID: 33296286
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inorganic arsenic induces sex-dependent pathological hypertrophy in the heart.
    Kabir R, Sinha P, Mishra S, Ebenebe OV, Taube N, Oeing CU, Keceli G, Chen R, Paolocci N, Rule A, Kohr MJ.
    Am J Physiol Heart Circ Physiol; 2021 Apr 01; 320(4):H1321-H1336. PubMed ID: 33481702
    [Abstract] [Full Text] [Related]

  • 17. Triad3A attenuates pathological cardiac hypertrophy involving the augmentation of ubiquitination-mediated degradation of TLR4 and TLR9.
    Lu X, He Y, Tang C, Wang X, Que L, Zhu G, Liu L, Ha T, Chen Q, Li C, Xu Y, Li J, Li Y.
    Basic Res Cardiol; 2020 Feb 01; 115(2):19. PubMed ID: 32008145
    [Abstract] [Full Text] [Related]

  • 18. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
    Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD.
    Circ Res; 2004 Jan 09; 94(1):110-8. PubMed ID: 14656927
    [Abstract] [Full Text] [Related]

  • 19. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
    Xu X, Zhang P, Kwak D, Fassett J, Yue W, Atzler D, Hu X, Liu X, Wang H, Lu Z, Guo H, Schwedhelm E, Böger RH, Chen P, Chen Y.
    Basic Res Cardiol; 2017 Aug 17; 112(5):55. PubMed ID: 28819685
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.